Nabilone
- Generic Name
- Nabilone
- Brand Names
- Cesamet
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36O3
- CAS Number
- 51022-71-0
- Unique Ingredient Identifier
- 2N4O9L084N
- Background
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however...
- Indication
Nabilone is indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Nabilone can be expected to experience disturbing psychotomimetic re...
- Associated Conditions
- Refractory Chemotherapy-Induced Nausea and Vomiting (CINV)
- Associated Therapies
- -
A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- Winnipeg Regional Health Authority
- Target Recruit Count
- 40
- Registration Number
- NCT00272207
- Locations
- 🇨🇦
Rehabilitation Hospital, Winnipeg, Manitoba, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.